News

National Institute for Health and Care Excellence11h
Published guidance, NICE advice and quality standards
Guidance programme Guidance programme Antimicrobial prescribing guidelines (20) Cancer service guidelines (8) Clinical guidelines (226) COVID-19 rapid guidelines (3) Diagnostics guidance (50) Health ...
The National Institute for Health and Care Excellence7d
Harnessing digital innovation for children's mental health
In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...
The National Institute for Health and Care Excellence12d
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS
The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...
National Institute for Health and Care Excellence2mon
New guideline will help cut falls and related hospital admissions for older and at-risk people - NICE
New guideline will help cut falls and related hospital admissions for older and at-risk people. Personalised assessments that consider factors including the hazards in a person’s home, and their ...
National Institute for Health and Care Excellence6d
Sparsentan for treating primary IgA nephropathy - NICE
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.. Last reviewed: 25 June 2025 Next review: This guidance will be reviewed if ...
National Institute for Health and Care Excellence12d
Overview | Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | Guidance | NICE
Your responsibility. This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected ...
National Institute for Health and Care Excellence13d
Spesolimab for treating generalised pustular psoriasis flares
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there ...
National Institute for Health and Care Excellence7d
Overview | Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies | Guidance | NICE
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.. Last reviewed: 24 June 2025 Next review: ...
National Institute for Health and Care Excellence1y
1 Recommendations | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE
HCL systems are recommended as an option for managing blood glucose levels in type 1 diabetes for children and young people. HCL systems are only recommended if they are procured at a cost-effective ...
National Institute for Health and Care Excellence5mon
Planning and delivering overweight and obesity services and interventions | Overweight and obesity management | Guidance | NICE
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...
National Institute for Health and Care Excellence3mon
First daily pill for endometriosis approved for NHS use | NICE
The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...